Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 178

Showing 1-25 of 178 citing articles:

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions
Peilin Lu, Dongxue Ruan, Meiqi Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 83
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Changsong Qi, Chang Liu, Jifang Gong, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2224-2234
Closed Access | Times Cited: 36
T cell dysfunction and therapeutic intervention in cancer
Caitlin C. Zebley, Dietmar Zehn, Stephen Gottschalk, et al.
Nature Immunology (2024) Vol. 25, Iss. 8, pp. 1344-1354
Closed Access | Times Cited: 23
CD8+ T cell-based cancer immunotherapy
Yanxia Chen, Dingning Yu, Hui Qian, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 19
HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 19
Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients
Tobias Tix, Mohammad Alhomoud, Roni Shouval, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 20, pp. 4690-4700
Closed Access | Times Cited: 18
Beyond the blood: expanding CAR T cell therapy to solid tumors
Uğur Uslu, Carl H. June
Nature Biotechnology (2024)
Closed Access | Times Cited: 17
Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung
Tianchuan Zhu, Yuchen Xiao, Zhenxing Chen, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Delivering living medicines with biomaterials
Tetsuhiro Harimoto, Wei‐Hung Jung, David Mooney
Nature Reviews Materials (2025)
Closed Access | Times Cited: 2
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease
Andrea R. Daamen, Peter E. Lipsky
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 696-699
Closed Access | Times Cited: 14
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
Irene Andreu-Saumell, Alba Rodríguez-García, Vanessa Mühlgrabner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells
Tengku Ibrahim Maulana, Claudia Teufel, Madalena Cipriano, et al.
Cell stem cell (2024) Vol. 31, Iss. 7, pp. 989-1002.e9
Open Access | Times Cited: 14
The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
Puneeth Guruprasad, Alberto Carturan, Yunlin Zhang, et al.
Nature Immunology (2024) Vol. 25, Iss. 6, pp. 1020-1032
Closed Access | Times Cited: 13
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
Daniel C. Kirouac, Cole Zmurchok, Denise Morris
npj Systems Biology and Applications (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Zhaokai Zhou, Yumiao Mai, Ge Zhang, et al.
Cancer Letters (2024) Vol. 598, pp. 217079-217079
Closed Access | Times Cited: 12
Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis
Sarah Ash, Rebecca Orha, Holly Mole, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e008608-e008608
Open Access | Times Cited: 11
Compressive stresses in cancer: characterization and implications for tumour progression and treatment
Julia A Linke, Lance L. Munn, Rakesh K. Jain
Nature reviews. Cancer (2024) Vol. 24, Iss. 11, pp. 768-791
Closed Access | Times Cited: 10
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Natalie Fuchs, Longfei Zhang, Laura Calvo‐Barreiro, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 68-68
Open Access | Times Cited: 9
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 9
CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
Kewen Qian, Guangyao Li, Shuyi Zhang, et al.
Deleted Journal (2024) Vol. 2, Iss. 2
Open Access | Times Cited: 9
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies
John B.A.G. Haanen, Christy Los, Giao Q. Phan, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 8
Advances in Radionuclide-Labeled Biological Carriers for Tumor Imaging and Treatment
Yaozhang Yang, Jing Wang, Yan Zhong, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access | Times Cited: 1
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Vidit Bhandarkar, Teresa Dinter, Stefani Spranger
Science Immunology (2025) Vol. 10, Iss. 103
Closed Access | Times Cited: 1
Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy
Zongliang Zhang, Nian Yang, Long Xu, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 9
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top